



Universiteit
Leiden
The Netherlands

The evolution of intractable Ménière's disease: attacks resolve over time

Gerritsen, F.R.; Schenck, A.A.; Locher, H.; Berg, R. van de; Benthem, P.P. van; Blom, H.M.

Citation

Gerritsen, F. R., Schenck, A. A., Locher, H., Berg, R. van de, Benthem, P. P. van, & Blom, H. M. (2024). The evolution of intractable Ménière's disease: attacks resolve over time. *Frontiers In Neurology*, 15. doi:10.3389/fneur.2024.1469276

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/4195869>

Note: To cite this publication please use the final published version (if applicable).



OPEN ACCESS

EDITED BY

Bert De Foer,
Sint Augustinus Hospital, Belgium

REVIEWED BY

Diego Kaski,
University College London, United Kingdom
Alfonso Scarpa,
University of Salerno, Italy

*CORRESPONDENCE

A. A. Schenck
✉ j.schenck@hagaziekenhuis.nl

RECEIVED 23 July 2024

ACCEPTED 24 September 2024

PUBLISHED 24 October 2024

CITATION

Gerritsen FR, Schenck AA, Locher H, van de Berg R, van Benthem PP and Blom HM (2024) The evolution of *intractable* Ménière's disease: attacks resolve over time. *Front. Neurol.* 15:1469276. doi: 10.3389/fneur.2024.1469276

COPYRIGHT

© 2024 Gerritsen, Schenck, Locher, van de Berg, van Benthem and Blom. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The evolution of *intractable* Ménière's disease: attacks resolve over time

F. R. Gerritsen^{1,2}, A. A. Schenck^{1,2*}, H. Locher^{2,3}, R. van de Berg⁴, P. P. van Benthem² and H. M. Blom^{1,2,5}

¹Department of Otorhinolaryngology, Haga Hospital, The Hague, Netherlands, ²Department of Otorhinolaryngology and Head & Neck Surgery, Leiden University Medical Center, Leiden, Netherlands, ³The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Vestibular Disorders, Department of Otorhinolaryngology and Head and Neck Surgery, School for Mental Health and Neuroscience (MHENS), Maastricht University Medical Centre, Maastricht, Netherlands, ⁵Department of Otorhinolaryngology, Antwerp University Hospital, Antwerp, Belgium

Introduction: Knowledge of the natural and temporal course of a disease is important when deciding if an intervention is appropriate. In the case of Ménière's disease (MD), there is some evidence that attacks diminish over time, but the topic remains controversial. A conservative approach to surgery is usually followed in northern Europe, and leads to strict patient selection before considering surgery. Here, we describe the evolution of vertigo attacks among a group of intractable MD patients in whom surgery was considered.

Methods: Retrospective cohort study in a Ménière's disease expert center. Patients with definite unilateral Ménière's disease and persisting vertigo attacks despite treatment with intratympanic steroid injections were included. All patients had been waitlisted for participation in a planned trial assessing non-ablative surgery. They were waitlisted between June 2016 and June 2021 without undergoing the surgical intervention. In September 2022, data were collected from patient's files and follow-up telephone interviews were conducted to assess the evolution of their vertigo attacks.

Results: Thirty-five patients (54% male, mean age of onset 52 years, 51% right sided) were included in the analysis. Twenty-five patients (71%) eventually declined surgery. Of the 33 patients with complete information on vertigo attacks, 21 (64%) were free of vertigo attacks upon data collection, after a median disease duration of 5.3 years. Patients who did undergo surgery, had longer duration of disease than patients who did not.

Discussion: Even in a population with intractable MD, most patients will experience relief of symptoms over time. On one hand, active treatment may accelerate relief of symptoms, but on the other hand, non-ablative therapies are of debatable effect and ablative intervention carries a risk of life long side effects. Therefore, any active intervention should be carefully considered.

KEYWORDS

Ménière's disease, vertigo, vestibular system, endolymphatic sac surgery, evolution of disease

1 Introduction

Ménière's disease (MD) can be a highly incapacitating disease, characterized by spontaneous attacks of vertigo, sensorineural hearing loss and aural symptoms such as aural fullness and tinnitus (1–3). Treatment strategies aim to prevent, or at least reduce, the frequency and severity of attacks (4, 5). Usually, a stepwise approach is followed, starting with the least invasive and non-ablative therapies, such as diet and lifestyle intervention, medication such as diuretics or betahistine, and intratympanic (IT) injections with corticosteroids. However, effectiveness for these treatment modalities is uncertain (6–10). If symptoms persist despite the mentioned treatments, the disease can be considered “intractable” and several ablative treatment modalities can be considered. This includes intratympanic injection with gentamicin, selective neurectomy of the vestibular nerve and labyrinthectomy. These interventions seem successful in controlling vertigo attacks, but irreversibly destruct vestibular function and involve risk of permanent damage to the cochlear system (11, 12). A non-ablative, indisputable effective treatment with long-term effect is yet to be discovered. However, understanding of the disease's evolution over time is essential in the process of developing new techniques.

Within the general MD population, the natural temporal evolution of vertigo attacks has been studied, albeit limited and with discordant outcomes. Moreover, it is important to realize that the patients in nearly every study were treated in some way, as it is considered unethical to completely refrain from treatment (13). This has led to a knowledge gap on the natural evolution of MD. Despite the lack of insight, several new treatment modalities were proposed in the past decades. In 2015, Saliba and colleagues introduced a novel surgical technique, referred to as “endolymphatic duct blockage” (EDB) (14). One prospective, controlled trial on this technique yielded high success rates of over 95% for EDB (14). However, the study was not blinded.

In Netherlands, treatments (both medical and surgical) require approval from the health care authorities before being allowed and reimbursed. In this decision, available literature is pivotal. Currently, EDB is a treatment that is not allowed as the publication of Saliba et al. contained methodological flaws. Therefore, a trial was designed to (re)assess effectiveness of EDB (15). As with every clinical trial, this study had a long startup phase, in which administrative, ethical and financial issues were addressed. In this period of approximately 5 years, patients were informed that the trial was upcoming. In all these patients, the disease was considered “intractable” because they did not experience relieve in symptoms despite treatment with medication (betahistine) and/or intratympanic injections with steroids. If patients were interested in participation in the trial, they were put on a waitlist. In the time between waitlisting and the start of the trial, the patients were regularly seen in the outpatient clinic and treated with regular treatments such as betahistine and intratympanic injections with steroids, depending on symptoms and patient's preference. When the trial opened for inclusion, all patients were contacted and invited to (officially) participate in the trial. To the surprise of the researchers, the majority of patients declined participation.

The surprising refusal of most patients to undergo surgery led to further analysis of this group of patients, as presented here. This dataset provided an opportunity to study the evolution of unilateral MD in the (once) most severely affected patients, without surgical

intervention. This could be of value for future counseling and research in MD patients, especially regarding this severely affected subgroup with intractable MD.

2 Methods

2.1 Study design

This study was a retrospective cohort study, conducted in an MD expert center. Data was extracted from patient files and complemented by a telephone interview. The protocol of this study was reviewed and approved by the Medical Research Ethics Committee Leiden-The Hague-Delft (number G21.186) and approved by the research board of the HagaHospital (number T21.102). Data collection took place in September 2022.

2.2 Patients and setting

Patients with MD were referred by their general practitioner or by otolaryngologists nationwide. If patients reported a high disease burden despite conservative treatment, they were informed about the upcoming EDB trial and information about the surgical interventions was provided. If patients met the inclusion criteria and provided verbal informed consent, they were waitlisted for participation in the trial. They were also informed that it was unknown when the trial would open for inclusion.


Inclusion criteria at the time of waitlisting were:

- Definite unilateral Ménière's disease according to diagnostic criteria of the Bárány Society (1)
- More than three patient-reported attacks in the 6 months prior to waitlisting.
- Still suffering vertigo attacks despite non-surgical treatment (e.g., anti-vertigo medication, vestibular rehabilitation therapy, and dietary and lifestyle modifications), including at least two intratympanic (IT) injection each with corticosteroids (dexamethasone, methylprednisolone or triamcinoloneacetonide).
- Age $\geq$ 18 years

Exclusion criteria:

- Severe disability (e.g., neurological, orthopaedic and cardiovascular), pregnancy or serious concurrent illness that might interfere with surgery or follow-up.
- Active additional neuro-otological disorders that may mimic MD [e.g., vestibular migraine, recurrent vestibulopathy, phobic postural vertigo, vertebrobasilar transient ischemic attacks (TIAs), vestibular schwannoma, congenital disorders, enlarged vestibular aqueduct (EVA) or genetic disorders (like DFNA9)].

The startup phase of the trial lasted from June 2016 until June 2021 (15). When recruitment for the trial started in June 2021, all patients on the waitlist were contacted and invited to participate in the trial. To assess evolution of attacks among these patients, they were



contacted again in September 2022 for a telephone interview. A timeline of events can be found in [Figure 1](#).

The primary outcome measure of this study was the proportion of patients that became free of vertigo attacks. “Free of vertigo attacks” was defined as the absence of vertigo attacks in the 6 months prior to data collection. The patients who were considered free of attack according to this definition, were collectively considered the attack-free population.

Secondary outcome measures were:

- The duration of disease, defined as the time between the first and last vertigo attack within the attack-free population.
- The proportion of patients that eventually underwent surgery.
- The therapeutic process prior to the (intended) surgery.
 - o The median treatment period, defined as the time between the first visit at the otolaryngologist in our center and the moment of data-collection.
 - o The median duration on the waiting list, defined as the time between the moment of waitlisting and the start of the EDB-trial.
 - o The median number of consultations at the otolaryngologist.
 - o The median amount of administered IT corticosteroid injections.
 - o A description of other received therapies.
- The hearing evolution, represented by the hearing loss between first and last known pure tone audiogram, as endorsed by recent guidelines (16).
 - o The mean bone conduction from the first and last known pure tone audiogram, calculated from the mean sensorineural pure-tone hearing threshold at 0.5, 1, 2 and 3 kHz.
 - o The 3 kHz was calculated by averaging 2 and 4 kHz (17).
- The residual symptoms, defined as persisting audiovestibular symptoms in attack-free patients.

Lastly, a subgroup analysis was performed. Patients were categorized in groups of patients who had eventually undergone surgery, patients who had undergone ablative therapy and patients who had undergone neither of these treatment modalities. Outcomes were compared between the groups.

2.3 Statistical analysis

Statistical analyses were performed using SPSS version 28. For continuous and discrete variables, the mean and standard deviation were calculated in case of normal distribution, in other cases the median and interquartile range (IQR) were calculated. For categorical variables, frequencies and proportions were calculated.

For the subgroup analyses, the appropriate statistical test was chosen per outcome. All tests compared unpaired data. All numerical data were tested for normality. If numerical data had a normal distribution, an unpaired t-test was performed. If there was no numerical distribution among numerical outcome data, a Mann–Whitney U-test was performed. In case of binary or nominal categorical data, a Chi-square test was performed.

In case of missing data, no imputation was performed. In the outcomes, the number of data points was mentioned.

3 Results

3.1 Patient characteristics

From June 2016 until June 2021, 446 MD patients visited the MD expert center. Forty-three MD patients were waitlisted for participation in the EDB-trial. Upon the current analyses, eight of these patients were excluded because they developed bilateral MD ($n=1$) or vestibular migraine ($n=1$), had undergone less than two IT injections with corticosteroids ($n=5$), or due to uncertainty concerning the diagnosis after further progress of the disease ($n=3$). Two patients had overlap of exclusion criteria. Eventually, 35 patients met the inclusion criteria for this study and were included.

A small male predominance (54%) was observed and the mean age of onset was 52 years-old (SD 13 years). The side of disease was evenly distributed (18 right ears versus 17 left ears). The median duration of follow-up was 3.9 years (IQR 1.4 years).

3.2 Evolution of vertigo attacks

Thirty-three out of 35 patients agreed with the telephone interview, and data on vertigo attacks were complete for these patients. Two patients could not be reached. Sixty-four percent (21/33) of the included patients were free of attacks upon the interview. Additionally, two patients were not free of attacks but had sufficient control of symptoms with intratympanic steroid injections.

The median total duration of disease in the attack-free population was 5.7 years (IQR 4.2 years) from the first symptoms until the last attack.

3.3 Treatment and therapeutic process

Of all 35 patients, data on surgical intervention were complete. Eighty percent (28/35) of the waitlisted patients did not undergo surgical intervention, after a median duration on the waiting list of 1.2 years (IQR 0.5). In 25 of 28 cases, this was the patient's choice. Two patients were excluded from surgery by the surgeons due to language difficulties ($n=1$) and previous radiotherapy at the surgery site ($n=1$). One patient was not operated due to ambiguity in patient's preferences. Seven patients eventually underwent surgical intervention, either in


the context of the trial or abroad. A flow chart of the (sub)groups can be found in [Figure 2](#).

Patients visited the otolaryngologist in the MD center for a median of 8 times (IQR 12) during a median treatment period of 2.4 years (IQR 3.4 years). The median amount of IT corticosteroids per patients was six (IQR 7 injections). Two patients underwent IT injections with gentamicin, 32 patients received anti-vertigo medication (betahistine, cinnarizine) and 18 patients were referred to a physiotherapist for vestibular rehabilitation therapy. All administered treatments can be found in [Supplementary Table S1](#).

3.4 Hearing evolution and residual symptoms

From 28 patients, multiple audiograms were available. The mean duration between first and last audiogram was 32.8 months (SD 25.1 months). The mean bone conduction at the first PTA was -41.6 dB ($n=33$, SD 22.7 dB), and -51.1 dB at the last PTA of the *affected* ear ($n=27$, SD 15.7 dB). This was a significant reduction in hearing ($p<0.001$). Of the *unaffected* ear, the mean bone conduction at the first audiogram was -13.3 dB ($n=33$, SD 8.9), and -15.7 dB at the last PTA ($n=27$, SD 12.3). This difference was significant as well ($p<0.001$), although the mean hearing loss was much smaller than in the affected ear (-10.5 dB versus -2.4 dB respectively).

The attack-free patients ($n=21$) reported hearing loss ($n=20$), tinnitus ($n=14$), unsteadiness ($n=11$) and aural fullness ($n=5$) as residual symptoms.



3.5 Subgroup analysis: non-surgical treatment vs. surgical treatment

Patients were divided into the following subgroups:

- Patients who underwent surgical intervention ($n=7$). All seven patients underwent non-ablative surgery, either in the context of the mentioned trial (EDB or endolymphatic sac decompressions), or abroad (EDB).
- Patients who underwent ablative therapy ($n=2$). In both cases, this concerned intratympanic injection with gentamicin.
- Patients who underwent neither surgical nor ablative therapy ($n=26$).

As the subgroup of ablative therapy comprised of only two patients, calculations were performed only on the other two groups. There was no difference in sex, age or side of disease among the groups. Moreover, the proportion of patients who were free of attacks was not statistically different between the groups (71% among the non-operated vs. 43% in the operated group, $p=0.46$) (see [Table 1a](#)). Patients who underwent surgery, had longer duration of disease (2,465 days among the non-operated vs. 3,604 days among the operated patients, $p=0.04$). This group also visited the ENT-consultant more often (15 vs. 8 times, $p=0.02$) and had more telephonic consultations (11 vs. 4, $p<0.001$) ([Table 1a](#)). The difference between the first and last PTA was not different between the groups ([Table 1b](#)). All outcomes and comparisons between the subgroups can be found in [Table 1](#).

4 Discussion

4.1 Evolution of disease

This study demonstrates that most patients (80%) who once opted for surgery as treatment for Ménière's disease, refused surgery after a relatively short period of waiting (mean 1.2 years). Apparently, this period of waiting was enough for symptoms to diminish or even dissolve completely. During follow-up, 64% ($n=21/33$) of the study population became free of vertigo attacks with a median duration of disease of 5.3 years (IQR 7.4 years).

As with every disease, knowledge of the natural course of the disease is imperative. Because of the intrusive nature of the disease, this is difficult to assess in MD: it could be considered unethical to refrain from any sort of treatment ([13](#)). This has led to the absence of data of patients who were not treated at all and in whom the "natural evolution" could be observed. The largest group of patients was reported by Perez-Garrigues, describing 510 patients who were treated only with oral medication ([18](#)). In the first years of disease, a rapid decline in number of vertigo attacks per year was seen, suggesting a benign evolution of MD. After 8 years, there was a stabilization in the decrease in attack frequency. Although it was stated that "most patients reach a vertigo-free state", no exact percentages were reported. Perez-Carbonell and colleagues reported a similar pattern of decreasing attacks among 327 patients ([19](#)). Findings of Friberg et al. among 161 patients also supported this conclusion ([20](#)). Other studies suggested a less fortunate course with vertigo attacks even after long-term follow-up ([21](#)), although generally in reduced frequency ([22](#)).

Thus, from the current body of literature, we can conclude that the general evolution of disease in patients suffering from MD is rather benign, with reduction of attacks over time.

However, in the current analysis, only patients with "intractable" disease were included; they suffered frequent attacks despite treatment with at least intratympanic corticosteroid injections ([Supplementary Table S1](#)). Comparison with a general MD population is therefore not appropriate, but there are some papers discussing the evolution of a subset of patients similar to the current population. Silverstein et al. report about a group of patients to whom surgery was offered, but was declined ([23](#)). After over 3 years of follow-up, 71% of the patients were free of attacks. This rate is comparable to the presented data. Green et al. report that 57% of this non-operated patients were free of vertigo attacks after 9 years of follow-up, a slightly smaller proportion than the present population ([24](#)). Sumi et al. report that 79% was free of vertigo after 10 or more years of follow-up, although three patients had undergone surgery ([25](#)).

Kerr and Toner reported a group of 23 patients whom were offered surgery ([26, 27](#)). Within 8 weeks, 12 patients experienced "dramatic improvement" and eventually refused surgery. They argue that this improvement might be due to the prospect of surgery, and that improvement after surgery, had they proceeded, should not be attributed to the surgery, but to the *idea* of surgery. Interestingly, the proportion of patients who improved in Kerr's paper was very similar this study, a group that also faced the prospect of surgery.

Together, these papers suggest that outcomes for patients to whom surgery is offered, is just as good as for the general MD population.

4.2 Surgical intervention

From the total MD population of 446 patients in the current center, 35 patients were included in the final analysis and only seven patients eventually underwent surgery. This is 1.5% of our total population. In other studies, this percentage is usually higher, about 10–20% of the total MD population ([19, 25, 28](#)). Green et al. even reported surgery in 34% of his 119 patients ([24](#)). The fact that the proportion of operated patients was substantially lower in our population than in other papers, may be explained by the "northern Europe approach" of treatment. The attitude towards surgery is usually very conservative, and surgical intervention is generally considered a "last resort". After the Danish RCT's of Thomsen and Bretlau, the perspective on non-ablative surgery is even more reserved ([29, 30](#)). Due to the restrictive policy on surgery, there is a strict patient selection for surgery, as was also the case for our patients. Therefore, our population consisted only of the most severely affected patients. Among this subgroup of 35 patients, 7 (20%) eventually underwent surgery. This was similar to the numbers reported by Haid et al., who report that 15% of their patients with intractable disease underwent surgery ([31](#)). This German research group may have had the same conservative approach to surgery, leading to similar surgery rates. The fact that geographical location may affect the decision for surgery, makes it hard to compare the outcomes of this study with most of the available literature.

However, from these data, it can be concluded that even among the most severely affected patients ("proven" by the fact that they were selected for surgery), symptoms diminish over time, with a substantial proportion of patients reaching an attack-free state.

TABLE 1 Subgroup analysis, subdivided in characteristics (a) and hearing (b).

	Subgroup analysis					
	Total	No surgical/ ablative therapy	Surgery	Ablative therapy	Appropriate statistical test	Subgroup comparison no invasive/ablative therapy vs surgery
	<i>n</i> = 35	<i>n</i> = 26	<i>n</i> = 7	<i>n</i> = 2		
<i>a. Characteristics</i>						
Sex					Chi square test (categorical binary outcome data)	<i>p</i> = 0.74
M	19 (54%)	13 (50%)	4 (57%)	2 (100%)		
F	16 (46%)	13 (50%)	3 (43%)	0 (0%)		
Side of disease					Chi square test (categorical binary outcome data)	<i>p</i> = 0.61
AD	18 (51%)	12 (46%)	4 (57%)	2 (100%)		
AS	17 (49%)	14 (54%)	3 (43%)	0 (0%)		
Outcome					Chi square test (categorical nominal outcome data)	<i>p</i> = 0.17
Free of attacks	21 (64%)	17 (71%)	3 (43%)	1 (50%)		
Not free of attacks	12 (36%)	7 (29%)	4 (57%)	1 (50%)		
Unknown	2	2	0	0		
Age at diagnosis (by ENT surgeon)					Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.19
Mean (range)	51 (21–74)	49 (21–72)	52 (36–67)	73 (72–74)		
SD	13.3	13	10	1.4		
Duration of disease (days)	<i>n</i> = 33	<i>n</i> = 24			Mann–Whitney U test (numerical data with no normal distribution)	<i>p</i> = 0.04
Mean (range)	3,006 (243–12,889)	2,465 (243–8,507)	3,604 (1,903–6,633)	7,403 (1,916–12,889)		
SD	2,599	1919	1963	7,759		
Consults with ENT-consultant					Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.02
Mean (range)	9 (1–29)	8 (1–20)	15 (5–29)	2 (1–3)		
SD	7	6	8	1		
Telephonic consults					Mann–Whitney U test (numerical data with no normal distribution)	<i>p</i> < 0.001
Mean (range)	6 (0–25)	4 (0–9)	11 (2–25)	4 (2–6)		
SD	5	3	7	3		
Number of IT injections					Mann–Whitney U test (numerical data with no normal distribution)	<i>p</i> = 0.78
Mean (range)	7 (2–20)	6 (2–17)	7 (2–18)	12 (3–20)		
SD	5	4	6	12		

(Continued)

TABLE 1 (Continued)

	Subgroup analysis					
	Total	No surgical/ ablative therapy	Surgery	Ablative therapy	Appropriate statistical test	Subgroup comparison no invasive/ablative therapy vs surgery
	<i>n</i> = 35	<i>n</i> = 26	<i>n</i> = 7	<i>n</i> = 2		
<i>b. Hearing</i>						
Mean bone conduction first PTA (<i>affected</i> side) (dB)	<i>n</i> = 33	<i>n</i> = 25		<i>n</i> = 1	Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.07
Mean (range)	−42 (−74 to −8)	−38 (−68 to −8)	−53 (−74 to −16)	−52		
SD	−19	−18	−19			
Mean bone conduction last PTA (<i>affected</i> side) (dB)	<i>n</i> = 27	<i>n</i> = 20	<i>n</i> = 6	<i>n</i> = 1	Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.40
Mean (range)	−51 (−76 to −14)	−49 (−75 to −14)	−55 (−76 to −44)	−67		
SD	−16	−17	−11			
Difference (<i>affected</i> side) (dB)	<i>n</i> = 26	<i>n</i> = 20	<i>n</i> = 6	NA (different patients)	Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.27
Mean (range)	−11 (−58 to +21)	−13 (−58 to +20)	−3 (−29 to +21)			
SD	−18	−18	−17			
Mean bone conduction first PTA (<i>unaffected</i> side) (dB)	<i>n</i> = 33	<i>n</i> = 25		<i>n</i> = 1	Mann–Whitney U test (numerical data with no normal distribution)	<i>p</i> = 0.56
Mean (range)	−13 (−36 to −2)	−13 (−316 to −2)	−15 (−36 to −3)	−14		
SD	−9	−9	−11			
Mean bone conduction last PTA (<i>unaffected</i> side) (dB)	<i>n</i> = 27	<i>n</i> = 20	<i>n</i> = 6	<i>n</i> = 1	Mann–Whitney U test (numerical data with no normal distribution)	<i>p</i> = 0.22
Mean (range)	−16 (−53 to −1)	−13 (−34.0 to −1)	−19 (−38 to −7)	−53		
SD	−12	−10	−11			
Difference (<i>unaffected</i> side) (dB)	<i>n</i> = 26	<i>n</i> = 20	<i>n</i> = 6	NA (different patients)	Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.20
Mean (range)	−1 (−18 to +9)	0 (−18 to +9)	−4 (−11 to +5)			
SD	−6	−6.5	−6			
WRS first PTA (<i>affected</i> side)	<i>n</i> = 19	<i>n</i> = 16	<i>n</i> = 3		Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.42
Mean (range)	77 dB (40–110)	75 dB (40–110)	85 dB (73–96)			
SD	18	19	12			

(Continued)

TABLE 1 (Continued)

	Subgroup analysis					
	Total	No surgical/ ablative therapy	Surgery	Ablative therapy	Appropriate statistical test	Subgroup comparison no invasive/ablative therapy vs surgery
	<i>n</i> = 35	<i>n</i> = 26	<i>n</i> = 7	<i>n</i> = 2		
WRS last PTA (<i>affected</i> side)	<i>n</i> = 23	<i>n</i> = 16	<i>n</i> = 5		Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.73
Mean (range)	82 dB (46–105)	81 dB (46–105)	84 dB (68–103)	85 dB (65–105)		
SD	17	18	16	28		
WRS difference (<i>affected</i> side)	<i>n</i> = 11	<i>n</i> = 10	<i>n</i> = 1			NA
Mean (range)	13 dB (–14 to 42)	13 dB (–14 to 42)	18 dB			
SD	19	20				
WRS first PTA (<i>unaffected</i> side)	<i>n</i> = 15	<i>n</i> = 12	<i>n</i> = 3		Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.86
Mean (range)	46 dB (31–60)	46 dB (31–57)	45 dB (34–60)			
SD	9	8	13			
WRS last PTA (<i>unaffected</i> side)	<i>n</i> = 17	<i>n</i> = 12	<i>n</i> = 3		Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.79
Mean (range)	45 dB (30–75)	43 dB (30–57)	45 dB (35–57)	57 dB (38–75)		
SD	12	10	11	26		
WRS difference (<i>unaffected</i> side)	<i>n</i> = 8	<i>n</i> = 6	<i>n</i> = 2		Unpaired t-test (numerical data with normal distribution)	<i>p</i> = 0.80
Mean (range)	1 dB (–10 to 17)	1 dB (–10 to 17)	–1 dB (–3 to 1)			
SD	9	10	3			

M, male; F, female; AD, right ear; AS, left ear; ENT, ear, nose, throat; SD, standard deviation; IT, intratympanic.
PTA, pure tone audiometry; dB, decibel; SD, standard deviation; WRS, word recognition score, the loudness at which 50% of the words was correctly heard by the patient.

4.3 To treat or not to treat?

Regarding the outcomes of attacks, time seems to have a favorable effect on attacks, even in the most severely affected patients. Interestingly, similar to the studies on the natural evolution of the disease, nearly every study on *active* intervention for MD also reports this “success rate”. Supporting literature can be found for all sorts of interventions; conservative treatments such as lifestyle and dietary changes (32), diuretics (33), betahistine (34). For more invasive therapies, such as intratympanic injections with corticosteroids (35) and intravenous glycerol (36), similar supporting literature can be found. For surgical interventions, such as shunting of the endolymphatic sac (37), endolymphatic sac decompression (38, 39), endolymphatic duct blockage (14) or triple semicircular canal plugging (40), results are also similar with success percentages ranging from 60 to 96%.

In general, outcomes of treatment can be attributed to the actual effect of the investigated treatment, the natural evolution of the disease, the placebo effect, regression to the mean or to any combination of these factors. Yet, it is impossible to differentiate between the five. Therefore, depending on personal experience, attitude and beliefs, one could believe that “everything” helps, that “nothing” helps or, very selectively, that the treatment of interest helps. However, compared to placebo and in RCTs and systematic reviews, neither treatment has proven to be convincingly effective (7–10, 41). Moreover, the currently endorsed way of measuring treatment outcomes (42), comparing 6 months before intervention with the 18–24 months interval after intervention, carry the risk of measuring only the regression to the mean, potentially distorting outcomes in all studies that follow these guidelines.

The only exception may be ablative therapy, once described by a patient as “euthanasia of the sick ear”. Although there are no RCTs comparing ablative surgical intervention such as labyrinthectomy or vestibular neurectomy to placebo surgery, there is some placebo-controlled evidence that intratympanic injection of gentamicin is an effective treatment, although limited (43, 44). The downside of any ablative therapy is the imminent damage that is inflicted on the vestibular system. In case of chemical ablation with gentamicin, it remains challenging to titrate the exact number of gentamicin injections necessary for effective treatment, and there may be an overshoot of iatrogenic vestibular hypofunction. In case of ablative surgery, vestibular areflexia is inevitable. Unilateral vestibular hypofunction leads to (at least) moderate handicap in over 30% of patients, even after vestibular rehabilitation therapy (45), meaning that patients might experience side effects for the rest of their lives. Another factor to take into account is the fact that MD may develop in the contralateral ear as well; in long term follow-up, bilateral disease is reported in up to 44% of the patients (20, 21, 46). With one labyrinth already afunctional as result of ablative therapy, patients may face complete deafness and serious balance and equilibrium problems. Therefore, ablative therapy should be very carefully considered.

In summary, non-ablative treatments are of debatable effect, ablative modalities carry a risk of life-long side effects, and, most importantly, there seems to be a decrease in attacks regardless of therapy. This leads to the question if patients with Ménière’s disease should ever be actively treated. Not doing so could protect patients from life-long treatment related side effects and save the health care

system money by refraining from non-effective therapies. Lastly, it could save the patients false hopes and subsequent disappointment in case of relapse of attacks. On the other side, MD is known to have severe impact on quality of life (2). Any improvement may be very beneficial for the patient, even if “only” caused by the placebo effect. Although the placebo effect is thought to have a peak and carry-over effect (47, 48), this may be sufficient to suppress symptoms until the expected natural decline in symptoms.

The results of this study are limited by several factors. Firstly, the sample size is small ($n=35$) and not all data are complete. This potentially affects generalizability of the results. The retrospective design of the study also poses a risk of (confounder) bias. Lastly, recall and non-response bias was potentially introduced by taking telephone interview. A prospective design could overcome these risks, and could also offer a broader look into relevant factor for patients with MD, such as quality of life. Ideally, such a study should be performed in a multicenter setting, to minimize the risk of bias.

5 Conclusion

The current data support the statement that about 70% of the patients suffering from Ménière’s disease will experience a decline in symptoms, regardless of severity of disease and therapy. The current population was thought to suffer intractable disease, and yet most patients experienced relieve of symptoms in just over 1 year. Knowledge of the generally benign evolution of Ménière’s disease may be of value for patients and clinicians when weighing treatment options.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Medical Research Ethics Committee Leiden-The Hague-Delft (number G21.186). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because only file data, and one telephone interview (non invasive) were conducted.

Author contributions

FG: Writing – original draft, Project administration, Methodology, Investigation, Formal analysis, Data curation. AS: Writing – review & editing, Writing – original draft, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. HL: Writing – review & editing, Supervision. RB: Writing – review & editing, Supervision. PB: Writing – review & editing, Supervision. HB: Writing – review & editing, Supervision, Conceptualization, Methodology.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was carried out within the framework of the EDB-trial. This trial is funded by National Health Care Institute through a grant for “promising care”, project number 80-86200-98-19017. HL was supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (Grant No. NNF21CC0073729).

Acknowledgments

The authors thank Isobel Bowring for her effort to proofread the manuscript, and Kimberley Koetsier for her advice on statistical issues.

Conflict of interest

HL was employed by The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW).

References

- Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al. Diagnostic criteria for Ménière's disease. *J Vestib Res.* (2015) 25:1–7. doi: 10.3233/VES-150549
- Anderson JP, Harris JP. Impact of Ménière's disease on quality of life. *Otol Neurotol.* (2001) 22:888–94. doi: 10.1097/00129492-200111000-00030
- Arroll M, Dancsey CP, Attree EA, Smith S, James T. People with symptoms of Ménière's disease: the relationship between illness intrusiveness, illness uncertainty, dizziness handicap, and depression. *Otol Neurotol.* (2012) 33:816–23. doi: 10.1097/MAO.0b013e3182536ac6
- Basura GJ, Adams ME, Monfared A, Schwartz SR, Antonelli PJ, Burkard R, et al. Clinical practice guideline: Ménière's disease. *Otolaryngol Head Neck Surg.* (2020) 162:1–55. doi: 10.1177/0194599820909438
- Liu Y, Yang J, Duan M. Current status on researches of Meniere's disease: a review. *Acta Otolaryngol.* (2020) 140:808–12. doi: 10.1080/00016489.2020.1776385
- Hussain K, Murdin L, Schilder AG. Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome. *Cochrane Database Syst Rev.* (2018) 2018. doi: 10.1002/14651858.CD012173.pub2
- Thirlwall AS, Kundu S. Diuretics for Ménière's disease or syndrome. *Cochrane Database Syst Rev.* (2006) 2006:CD003599. doi: 10.1002/14651858.CD003599.pub2
- Adrian C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). *BMJ (Clin Res Ed).* (2016) 352:h6816. doi: 10.1136/bmj.h6816
- Webster KE, George B, Lee A, Galbraith K, Harrington-Benton NA, Judd O, et al. Lifestyle and dietary interventions for Ménière's disease. *Cochrane Database Syst Rev.* (2023) 2023. doi: 10.1002/14651858.CD015244.pub2
- Webster KE, Lee A, Galbraith K, Harrington-Benton NA, Judd O, Kaski D, et al. Intratympanic corticosteroids for Ménière's disease. *Cochrane Database Syst Rev.* (2023) 2023. doi: 10.1002/14651858.CD015245.pub2
- Pullens B, Van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. *Cochrane Database Syst Rev.* (2011) 3:CD008234. doi: 10.1002/14651858.CD008234
- Pullens B, Verschuur HP, Van Benthem PP. Surgery for Ménière's disease. *Cochrane Database Syst Rev.* (2013) 2013:CD005395. doi: 10.1002/14651858.CD005395.pub3
- Filipo R, Barbara M. Natural history of Ménière's disease: staging the patients or their symptoms? *Acta Otolaryngol Suppl.* (1997) 526:10–3. doi: 10.3109/00016489709124013
- Saliba I, Gabra N, Alzahrani M, Berbiche D. Endolymphatic duct blockage: a randomized controlled trial of a novel surgical technique for Ménière's disease treatment. *Otolaryngol Head Neck Surg.* (2015) 152:122–9. doi: 10.1177/0194599814555840
- Schenck AA, Krut JM, van Benthem PP, Cannegieter SC, van den Hout WB, Böhringer S, et al. Effectiveness of endolymphatic duct blockage versus endolymphatic

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2024.1469276/full#supplementary-material>

- sac decompression in patients with intractable Ménière's disease: study protocol for a double-blinded, randomised controlled trial. *BMJ Open.* (2021) 11:e054514. doi: 10.1136/bmjopen-2021-054514
- Gurgel RK, Jackler RK, Dobie RA, Popelka GR. A new standardized format for reporting hearing outcome in clinical trials. *Otolaryngol Head Neck Surg.* (2012) 147:803–7. doi: 10.1177/0194599812458401
- Gurgel RK, Popelka GR, Oghalai JS, Blevins NH, Chang KW, Jackler RK. Is it valid to calculate the 3-kilohertz threshold by averaging 2 and 4 kilohertz? *Otolaryngol Head Neck Surg.* (2012) 147:102–4. doi: 10.1177/0194599812437156
- Perez-Garrigues H, Lopez-Escamez JA, Perez P, Sanz R, Orts M, Marco J, et al. Time course of episodes of definitive vertigo in Meniere's disease. *Arch Otolaryngol Head Neck Surg.* (2008) 134:1149–54. doi: 10.1001/archotol.134.11.1149
- Pérez-Carbonell T, Orts-Alborch M, Pérez-Guillén V, Tenías-Burillo JM, Pla-Gil I, Marco-Algarra J, et al. A longitudinal study of unilateral Ménière's disease and clinical evolutionary models. *J Laryngol Otol.* (2023) 137:629–36. doi: 10.1017/S00222515122001773
- Friberg U, Stahle J, Svedberg A. The natural course of Meniere's disease. *Acta Otolaryngol Suppl.* (1984) 406:72–7.
- Havia M, Kentala E. Progression of symptoms of dizziness in Ménière's disease. *Arch Otolaryngol Head Neck Surg.* (2004) 130:431–5. doi: 10.1001/archotol.130.4.431
- Stahle J, Friberg U, Svedberg A. Long-term progression of Meniere's disease. *Am J Otol.* (1989) 10:170–3.
- Silverstein H, Smouha E, Jones R. Natural history vs. surgery for Meniere's disease. *Otolaryngol Head Neck Surg.* (1989) 100:6–16. doi: 10.1177/019459988910000102
- Green JD Jr, Blum DJ, Harner SG. Longitudinal followup of patients with Ménière's disease. *Otolaryngol Head Neck Surg.* (1991) 104:783–8. doi: 10.1177/019459989110400603
- Sumi T, Watanabe I, Tsunoda A, Nishio A, Komatsuzaki A, Kitamura K. Longitudinal study of 29 patients with Meniere's disease with follow-up of 10 years or more (in commemoration of professor emeritus Isamu Watanabe). *Acta Otolaryngol.* (2012) 132:10–5. doi: 10.3109/00016489.2011.627570
- Kerr AG, Toner JG. A new approach to surgery for Ménière's disease: talking about surgery. *Clin Otolaryngol Allied Sci.* (1998) 23:263–4. doi: 10.1046/j.1365-2273.1998.00153.x
- Kerr AG. Statistical errors in "a new approach to surgery for Ménière's disease". *Clin Otolaryngol Allied Sci.* (1999) 24:81.
- Kitahara T. Evidence of surgical treatments for intractable Meniere's disease. *Auris Nasus Larynx.* (2018) 45:393–8. doi: 10.1016/j.anl.2017.07.016
- Bretlau P, Thomsen J, Tos M, Johnsen NJ. Placebo effect in surgery for Ménière's disease: nine-year follow-up. *Am J Otol.* (1989) 10:259–61.
- Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for Ménière's disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery. *Arch Otolaryngol.* (1981) 107:271–7. doi: 10.1001/archotol.1981.00790410009002

31. Haid CT, Watermeier D, Wolf SR, Berg M. Clinical survey of Menière's disease: 574 cases. *Acta Otolaryngol Suppl.* (1995) 115:251–5. doi: 10.3109/00016489509125240
32. Jackson CG, Glasscock ME 3rd, Davis WE, Hughes GB, Sismanis A. Medical management of Menière's disease. *Ann Otol Rhinol Laryngol.* (1981) 90:142–7. doi: 10.1177/000348948109000209
33. Klockhoff I, Lindblom U, Stahle J. Diuretic treatment of Meniere disease. Long-term results with chlorthalidone. *Arch Otolaryngol.* (1974) 100:262–5. doi: 10.1001/archotol.1974.00780040272004
34. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. *Eur Arch Otorhinolaryngol.* (2003) 260:73–7. doi: 10.1007/s00405-002-0524-4
35. Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by Intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. *Otolaryngol Head Neck Surg.* (2005) 133:285–94. doi: 10.1016/j.otohns.2005.05.010
36. Scarpa A, Carucci M, Salzano G, Avallone E, Cassandro C, De Luca P, et al. Enhancing the therapeutic potential of intravenous glycerol for Meniere's disease: robust results from an extensive patient cohort. *Am J Otolaryngol.* (2024) 45:104093. doi: 10.1016/j.amjoto.2023.104093
37. Spiegel JL, Stoycheva I, Weiss BG, Bertlich M, Rader T, Canis M, et al. Vestibular and audiometric results after endolymphatic mastoid shunt surgery in patients with Menière's disease. *Eur Arch Otorhinolaryngol.* (2023) 280:1131–45. doi: 10.1007/s00405-022-07582-6
38. Conway RM, Babu SC, Mallany P, Weymon A, Wilkerson BJ. Endolymphatic sac decompression effect on secondary symptoms of Meniere's disease. *Am J Otolaryngol.* (2023) 44:103777. doi: 10.1016/j.amjoto.2022.103777
39. Durland WF Jr, Pyle GM, Connor NP. Endolymphatic sac decompression as a treatment for Meniere's disease. *Laryngoscope.* (2005) 115:1454–7. doi: 10.1097/01.mlg.0000171017.41592.d0
40. Zhang D, Fan Z, Han Y, Lv Y, Li Y, Wang H. Triple semicircular canal plugging: a novel modality for the treatment of intractable Meniere's disease. *Acta Otolaryngol.* (2016) 136:1230–5. doi: 10.1080/00016489.2016.1206966
41. Lee A, Webster KE, George B, Harrington-Benton NA, Judd O, Kaski D, et al. Surgical interventions for Ménière's disease. *Cochrane Database Syst Rev.* (2023) 2:Cd015249. doi: 10.1002/14651858.CD015249.pub2
42. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. *Otolaryngol Head Neck Surg.* (1995) 113:181–5. doi: 10.1016/S0194-5998(95)70102-8
43. Diamond C, O'Connell DA, Hornig JD, Liu R. Systematic review of intratympanic gentamicin in Meniere's disease. *J Otolaryngol.* (2003) 32:351–61. doi: 10.2310/7070.2003.13863
44. Webster KE, Galbraith K, Lee A, Harrington-Benton NA, Judd O, Kaski D, et al. Intratympanic gentamicin for Ménière's disease. *Cochrane Database Syst Rev.* (2023) 2023. doi: 10.1002/14651858.CD015246.pub2
45. Karabulut M, Van Laer L, Hallemans A, Vereeck L, Van Rompaey V, Viechtbauer W, et al. Chronic symptoms in patients with unilateral vestibular hypofunction: systematic review and meta-analysis. *Front Neurol.* (2023) 14:1177314. doi: 10.3389/fneur.2023.1177314
46. Stahle J. Advanced Meniere's disease. A study of 356 severely disabled patients. *Acta Otolaryngol.* (1976) 81:113–9. doi: 10.3109/00016487609107484
47. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. *JAMA.* (1994) 271:1609–14. doi: 10.1001/jama.1994.03510440069036
48. Wartolowska KA, Feakins BG, Collins GS, Cook J, Judge A, Rombach I, et al. The magnitude and temporal changes of response in the placebo arm of surgical randomized controlled trials: a systematic review and meta-analysis. *Trials.* (2016) 17:589. doi: 10.1186/s13063-016-1720-7